PAVM
PAVmed Inc. NASDAQ$8.13
Mkt Cap $4.4M
52w Low $6.00
9.5% of range
52w High $28.44
50d MA $9.67
200d MA $11.34
P/E (TTM)
-1.5x
EV/EBITDA
-544.4x
P/B
0.3x
Debt/Equity
393.0x
ROE
1.2%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
0.81
50d MA
$9.67
200d MA
$11.34
Avg Volume
70.8K
About
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipel…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -4.50 | -2.05 | +54.4% | 8.94 | +0.0% | -3.0% | +9.6% | +13.5% | +14.5% | +10.2% | — |
| Nov 13, 2025 | AMC | -6.01 | -8.41 | -39.9% | 10.61 | +1.8% | -9.5% | +8.6% | +7.4% | +9.3% | +0.8% | — |
| Aug 14, 2025 | AMC | -0.25 | -0.05 | +80.0% | 13.69 | -1.4% | -1.5% | -5.5% | -6.0% | -8.0% | -7.7% | — |
| May 15, 2025 | AMC | -0.29 | -0.07 | +75.9% | 18.90 | +0.0% | +3.0% | -0.1% | +0.0% | +0.1% | +3.2% | — |
| Mar 25, 2025 | AMC | -0.40 | -0.06 | +85.0% | 22.79 | +6.4% | +7.3% | +1.1% | -1.3% | -5.0% | -7.9% | — |
| Nov 13, 2024 | AMC | -1.30 | -0.54 | +58.5% | 30.60 | +0.0% | +6.9% | +11.8% | +0.0% | +0.0% | +1.0% | — |
| Aug 13, 2024 | AMC | -1.45 | -0.84 | +42.1% | 22.20 | -2.7% | -2.7% | -5.3% | -8.2% | -6.8% | -5.4% | — |
| May 13, 2024 | AMC | -1.67 | -0.99 | +40.7% | 57.60 | +7.8% | +15.6% | -1.0% | -2.1% | -6.8% | -4.7% | — |
| Mar 26, 2024 | AMC | -1.89 | -1.33 | +29.6% | 61.80 | +12.6% | +32.5% | +3.9% | -1.0% | -1.0% | +12.1% | — |
| Nov 14, 2023 | AMC | -0.14 | -1.35 | -864.3% | 99.32 | +0.8% | +0.1% | +0.2% | -1.2% | -0.7% | -6.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $9.84 | $9.62 | -2.2% | -1.0% | -6.1% | -5.7% | -6.9% | -5.2% |
| Dec 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $11.04 | $10.74 | -2.7% | -2.4% | -4.9% | -10.3% | -15.0% | -16.6% |
| Oct 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $13.07 | $13.50 | +3.3% | +3.2% | +11.5% | +9.0% | +12.2% | +12.2% |
| Jun 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $18.95 | $18.58 | -2.0% | +0.0% | +1.7% | +5.0% | +9.2% | +7.4% |
| Apr 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $21.30 | $21.90 | +2.8% | -7.7% | -1.4% | +8.5% | +6.3% | +7.0% |
| Dec 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $29.10 | $28.80 | -1.0% | -12.1% | -12.4% | -16.5% | -19.6% | -21.2% |
| Aug 17 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $113.72 | $122.54 | +7.8% | -4.8% | -4.0% | -9.4% | -13.8% | -6.5% |
| Jan 19 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $215.10 | $225.00 | +4.6% | -4.0% | -4.6% | -1.7% | +0.0% | -3.8% |
| Jan 17 | Lake Street | Maintains | Buy → Buy | — | $263.34 | $256.50 | -2.6% | +8.1% | -18.3% | -21.6% | -22.1% | -19.7% |
| Aug 16 | Lake Street | Maintains | Buy → Buy | — | $1021.50 | $972.00 | -4.8% | -12.8% | -39.6% | -36.6% | -47.1% | -44.1% |
Recent Filings
8-K · 8.01
!! High
Lucid Diagnostics Inc. -- 8-K 8.01: Material Event / Announcement
Lucid Diagnostics raised $16.8 million net proceeds by selling 18 million common shares at $1.00 each in an underwritten public offering, strengthening its balance sheet for operations.
Apr 24
8-K
Unknown — 8-K Filing
I need the complete filing information to provide an accurate analysis. The summary appears incomplete and doesn't clearly specify which company (DRIO, LUCD, or PAVM) filed what action, making it impossible to assess the material impact on shareholders.
Apr 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
PAVmed's business update on subsidiary Lucid Diagnostics (LUCD) could signal strategic developments or financial milestones affecting both companies' near-term trajectories and investor positioning.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PAVM refinanced debt and redeemed preferred stock, potentially improving capital structure and reducing financial obligations, which could strengthen the balance sheet and enhance shareholder value long-term.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Lucid Diagnostics processed modest test volumes (3,664 units) with $1.5M quarterly revenue while securing VA contract access, suggesting early commercialization traction but limited scale requiring investor patience on profitability timeline.
Mar 26
8-K · 1.01
!! High
PAVmed Inc. -- 8-K 1.01: Material Agreement
PAVmed issued 60,000 shares of Series D Preferred Stock with a $6.50 conversion price, expanding its capital structure and providing new financing flexibility for the medical device company.
Feb 4
Data updated apr 26, 2026 6:41pm
· Source: massive.com